TI
REGN icon

Telemetry Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Telemetry Investments’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,500
Closed -$1.4M – 94
2020
Q3 		$1.4M Hold
2,500
– – 3.04% 7
2020
Q2 		$1.56M Buy
+2,500
New +$1.42M 4.23% 4
2018
Q3 		– Sell
-900
Closed -$310K – 144
2018
Q2 		$310K Buy
+900
New +$281K 0.12% 86

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Telemetry Investments's REGN Position: Q4 2020 in Review

Telemetry Investments sold out of Regeneron Pharmaceuticals (REGN) in Q4 2020, closing a stake of 2,500 shares — an estimated $1.4M sold.

Telemetry Investments first reported a position in REGN in Q2 2018 and held it in 3 quarters. The position peaked at $1.56M in Q2 2020. 904 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

  • Telemetry Investments reported no remaining Regeneron Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Telemetry Investments sold 2,500 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $1.4M.
  • Telemetry Investments first reported a position in Regeneron Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Telemetry Investments's Regeneron Pharmaceuticals position peaked at $1.56M in Q2 2020.
  • 904 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on Telemetry Investments's 13F filing for Q4 2020, filed 16 Feb 2021.